Positive opinion supports expanded treatment access
Category: News
Regulatory progress supports accelerated approval pathway
Positive phase 2 data supports ETD001 designation
RNA therapy reduces triglycerides and pancreatitis risk
New maintenance option after first-line chemotherapy
First participant enters treatment extension phase
Pfizer first company to join VIDAL service
£8m initiative to support cancer discovery
Phase 2 data expected during 2027
